IL17A and systemic lupus erythematosus: Furthermore, in the NZB/W F1 mouse model of lupus, MHV370 administration led to disease arrest.506 Inhibitors such as IMO-3100 and IMO-8400, which target these receptors, markedly diminish IL-23-induced IL-17A expression, highlighting their potential in modulating the inflammatory cascade.590 Research has shown that inhibitory oligodeoxynucleotides (ODNs) containing phosphorothioate backbone modifications possess therapeutic potential for immune-related diseases, including SLE and RA.